Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $15.86 Average Target Price from Brokerages

Tango Therapeutics, Inc. (NASDAQ:TNGX) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $18.25.

TNGX has been the topic of several recent research reports. Piper Sandler increased their target price on shares of Tango Therapeutics from $11.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Tango Therapeutics in a report on Wednesday, January 21st. Guggenheim upped their price target on shares of Tango Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday. Wolfe Research assumed coverage on shares of Tango Therapeutics in a research note on Tuesday, November 18th. They set a “peer perform” rating on the stock. Finally, Jefferies Financial Group reissued a “buy” rating and set a $18.00 price objective on shares of Tango Therapeutics in a report on Thursday.

Tango Therapeutics Trading Up 0.7%

Shares of TNGX stock opened at $16.95 on Friday. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $17.63. The stock has a fifty day simple moving average of $11.86 and a two-hundred day simple moving average of $9.48. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of -19.48 and a beta of 1.76.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. Research analysts predict that Tango Therapeutics will post -1.19 EPS for the current fiscal year.

Insider Buying and Selling at Tango Therapeutics

In other news, CFO Daniella Beckman sold 10,317 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $126,486.42. Following the completion of the transaction, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at approximately $2,259,481.22. The trade was a 5.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Barbara Weber sold 30,519 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $374,162.94. Following the sale, the director owned 1,629,254 shares of the company’s stock, valued at $19,974,654.04. This trade represents a 1.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 113,633 shares of company stock valued at $1,420,857. 7.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tango Therapeutics

A number of large investors have recently added to or reduced their stakes in TNGX. CWM LLC raised its holdings in Tango Therapeutics by 182.2% in the second quarter. CWM LLC now owns 4,905 shares of the company’s stock worth $25,000 after purchasing an additional 3,167 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of Tango Therapeutics in the 4th quarter valued at about $35,000. Dynamic Technology Lab Private Ltd grew its position in shares of Tango Therapeutics by 139.7% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after buying an additional 15,037 shares during the last quarter. Legal & General Group Plc grew its position in shares of Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after buying an additional 1,640 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Tango Therapeutics by 78.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock worth $40,000 after acquiring an additional 3,452 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors.

Tango Therapeutics News Roundup

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS‑0015/vopimetostat in MTAP‑deleted, RAS‑mutant cancers expands Tango’s clinical footprint and creates near‑term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy‑side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share‑price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell‑side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I’m Not Buying Into Latest Rally

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.